NasdaqGS:TXGLife Sciences
Is 10x Genomics (TXG) Quietly Recasting Its Product-Led Story After a Mixed Q1 Beat?
In the past quarter, 10x Genomics reported Q1 results that surpassed revenue and earnings estimates, even as revenue saw a slight year-on-year decline, and management reaffirmed full-year guidance.
Management also highlighted strong uptake of newer single cell and spatial consumables like FLEX Apex and Atara, with robust Atara preorders helping offset delays in purchases of older spatial instruments.
Now we’ll examine how this earnings beat and reaffirmed guidance might influence 10x...